Clinical trial
A Phase 1/2 Study of Edasalonexent (CAT-1004) in Pediatric Patients With Duchenne Muscular Dystrophy
NCT02439216 is registered in ClinicalTrials.gov with Catabasis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Study of Edasalonexent (CAT-1004) in Pediatric Patients With Duchenne Muscular Dystrophy
- Lead sponsor
- Catabasis Pharmaceuticals
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- April 30, 2016
- Completion date
- August 31, 2019
- Enrollment
- 31 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.